Vertex and bluebird bio, the companies behind the competing sickle-cell treatments approved in December, have provided new details in their plans to bring the treatments to patients in 2024. Bluebird said 26 patients started treatment in 2023 across its commercial portfolio. The company expects its first patient start for Lyfgenia in Q1 2024, and to hit between 85 to 105 patient starts in 2024 across its three approved therapies.
